The ryanodine receptor in cardiac physiology and disease.
The ryanodine receptor in cardiac physiology and disease.
复制标题
DOI：
10.1016/s1054-3589(10)59001-x
复制
发表时间：
2010
期刊：
影响因子：
--
通讯作者：
Marks AR
中科院分区：
文献类型：
--
作者：
Kushnir A;Marks AR
据美国心脏协会估计，2010年美国将花费近390亿美元治疗500多万患有心力衰竭的美国人。心力衰竭患者会出现呼吸困难和运动耐力下降，并有更高的致死性室性心律失常风险。美国食品和药物管理局批准的治疗心力衰竭的药物包括利尿剂、肾素-血管紧张素系统抑制剂和β-肾上腺素能受体拮抗剂。在过去的20年里，兰尼定受体(RyR2)/钙释放通道的研究进展极大地促进了我们对心脏生理学以及心力衰竭和心律失常发病机制的了解。在这里，我们回顾了主要的观察结果、争议和发现，这些发现导致了针对RyR2/钙释放通道的新化合物的开发，用于治疗心力衰竭和预防致命的心律失常。
According to the American Heart Association it is estimated that the United States will spend close to $39 billion in 2010 to treat over five million Americans suffering from heart failure. Patients with heart failure suffer from dyspnea and decreased exercised tolerance and are at increased risk for fatal ventricular arrhythmias. Food and Drug Administration -approved pharmacologic therapies for heart failure include diuretics, inhibitors of the renin–angiotensin system, and β-adrenergic receptor antagonists. Over the past 20 years advances in the field of ryanodine receptor (RyR2)/calcium release channel research have greatly advanced our understanding of cardiac physiology and the pathogenesis of heart failure and arrhythmias. Here we review the key observations, controversies, and discoveries that have led to the development of novel compounds targeting the RyR2/calcium release channel for treating heart failure and for preventing lethal arrhythmias.